ClinicalTrials.gg
RecruitingNCT07197944EASE SBS 5Updated Sep 29, 2026

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

A Phase 3 interventional study of Glepaglutide and Placebo in Short Bowel Syndrome, sponsored by Zealand Pharma. Recruiting at 33 sites in 14 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Zealand Pharma · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Sep 29, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 80 studies in Short Bowel Syndrome with a site in United States — 11 open to participants now, 15 under way, 4 of them phase 3. Short Bowel Syndrome · United States.

Planned enrollment
11th of 66
90 · median 23
Started
2026
with 1 other
Phase 3
20 of 80
2 open now
Primary completion
2028-10
later than 9 of 14 live
Registered
78th of 80
by date
Lead sponsor
5 of 80
Zealand Pharma

Among the 80 studies in Short Bowel Syndrome with a site in United States, this one is the 11th largest by planned enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2026, is one of 20 in phase 3, reaches primary completion later than 9 of the 14 other live ones, and was the 78th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

11 of the 80 studies in Short Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Short Bowel Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data.

Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.

Read the detailed description

The trial is a phase 3, double-blind, randomized, parallel-group, placebo-controlled, multicenter trial to confirm the efficacy and safety of glepaglutide 10 mg twice weekly, followed by a long-term, open-label safety evaluation in patients with short bowel syndrome-intestinal failure (SBS-IF).

03

Conditions studied

  • Short Bowel Syndrome

Keywords

  • Intestinal Failure
  • Pathologic Processes
  • Malabsorption Syndromes
  • Intestinal Diseases
  • Gastrointestinal Diseases
  • Digestive System Diseases
  • Postoperative Complications
  • Short Bowel Syndrome
  • Syndrome
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Signed ;
  • Age of 18 to 90 years;
  • A diagnosis of SBS, defined as having a small bowel with an estimated length of less than 200 cm (equal to 79 inches) in continuity (latest intestinal resection ≥6 months before screening);
  • Stable PS need of ≥3 days per week;
  • No restorative surgery planned during the trial period;
  • Having a stoma or colon in continuity.

Key Exclusion Criteria:

  • More than 2 SBS- or PS-related hospitalizations within 6 months before screening;
  • Poorly controlled Inflammatory Bowel Disease (IBD) that is moderately or severely active or a fistula that can interfere with the measurements or examinations required in the trial;
  • History of colorectal cancer or any other type of cancer (except for margin-free resected cutaneous basal, squamous cell carcinoma or adequately treated in situ cervical cancer) unless the patient has been disease-free for at least 5 years; ongoing bowel obstruction;
  • \<18.5 kg/m\^2.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Glepaglutide Group

    Drug: Glepaglutide

  • Placebo comparator
    Placebo Group

    Placebo for glepaglutide

    Other: Placebo

Interventions

  • Subcutaneous (SC) injections twice weekly

    Also known as: ZP1848

  • OtherPlacebo

    SC injections twice weekly

06

What researchers measure

Primary outcomes

  1. Change in weekly Parenteral Support (PS) volume

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Proportion of participants achieving clinical response

    Defined as achieving a reduction of at least 20% in weekly PS volume

    Time frame: Baseline to Week 52

  2. Proportion of participants achieving clinical response

    Defined as achieving a reduction of at least 20% in weekly PS volume

    Time frame: Baseline to Week 20 and Week 24

  3. Proportion of participants with a reduction in days on PS ≥1 day/week

    Time frame: Baseline to Week 52

  4. Proportion of participants with a reduction in days on PS ≥1 day/week

    Time frame: Baseline to Week 24

  5. Proportion of participants with a reduction of 100% weekly PS volume (weaned-off)

    Time frame: Baseline to Week 52

  6. Proportion of participants with a reduction of 100% weekly PS volume (weaned-off)

    Time frame: Baseline to Week 24

  7. Proportion of participants achieving 'much better' Patient Global Impression of Change (PGIC) status

    PGIC scoring categories are: 'Much better', 'A little better', 'No change', 'A little worse', and 'Much worse'

    Time frame: Week 24

  8. Change in weekly PS volume

    Time frame: Baseline to Week 12

  9. Change in weekly PS volume

    Time frame: Baseline to Week 8

  10. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Baseline to Week 52

07

Study locations

32 of 33 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2028, 32 months after the start.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 32 months is below that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Sep 30, 2025
StartActual
Feb 11, 2026
Primary completionEst.
Oct 23, 2028
CompletionEst.
Feb 28, 2032
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (1 United States, 1 Poland)
  • UPMC Starzl Transplantation Institute · Pittsburgh, United States
  • Szpital Skawina sp. z o.o. im. Stanley Dudricka · Skawina, Poland
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    2 sites added
    Show 2 added (1 United States, 1 Poland)
    • UPMC Starzl Transplantation Institute · Pittsburgh, United States
    • Szpital Skawina sp. z o.o. im. Stanley Dudricka · Skawina, Poland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07197944
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Feb 11, 2026
Primary completion
Oct 23, 2028 (estimated)
Completion
Feb 28, 2032 (estimated)
Last update
Sep 29, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glepaglutide

Start the discussion